

## Clinical Policy: Dupilumab (Dupixent)

Reference Number: CP.PHAR.336

Effective Date: 05.01.17

Last Review Date: 02.18

Line of Business: Commercial, Health Insurance Marketplace, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Dupilumab (Dupixent<sup>®</sup>) is an interleukin-4 receptor alpha antagonist.

### FDA Approved Indication(s)

Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

### Policy/Criteria

*Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Dupixent is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Atopic Dermatitis (must meet all):

1. Diagnosis of atopic dermatitis;
2. Prescribed by or in consultation with a dermatologist;
3. Age  $\geq$  18 years;
4. Failure of all of the following (a, b, and c) unless contraindicated or clinically significant adverse effects are experienced:
  - a. Two formulary medium to very high potency topical corticosteroids, each trialed for  $\geq$  2 weeks;
  - b. One non-steroidal topical therapy\*: topical calcineurin inhibitor (e.g., tacrolimus 0.03% ointment and pimecrolimus 1% cream) or Eucrisa, each trialed for  $\geq$  4 weeks;  
*\* These agents may require prior authorization*
  - c. One or more of the following systemic agents: corticosteroids, azathioprine, methotrexate, mycophenolate mofetil, or cyclosporine;
5. Dose does not exceed the following:
  - a. Initial (one-time) dose: 600 mg SC;
  - b. Maintenance dose: 300 mg SC every other week.

**Approval duration: 16 weeks**

##### B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Atopic Dermatitis** (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy (e.g., reduction in itching/scratching);
3. If request is for a dose increase, new dose does not exceed 300 mg SC given every other week.

**Approval duration: 12 months**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

| Drug   | Dosing Regimen                              | Dose Limit/<br>Maximum Dose |
|--|---|-----------------------------|
| <b>Very High Potency Topical Corticosteroids</b>                           |   |                             |
| augmented betamethasone 0.05% (Diprolene® AF) cream, ointment, gel, lotion | Apply topically to the affected area(s) BID | varies                      |
| clobetasol propionate 0.05% (Temovate®) cream, ointment, gel, solution     |   |                             |

|   |  |        |
|---|--|--------|
| diflorasone diacetate 0.05% (Maxiflor <sup>®</sup> , Psorcon E <sup>®</sup> ) cream, ointment                             |  |        |
| halobetasol propionate 0.05% (Ultravate <sup>®</sup> ) cream, ointment  |  |        |
| <b>High Potency Topical Corticosteroids</b>   |  |        |
| augmented betamethasone 0.05% (Diprolene <sup>®</sup> AF) cream, ointment, gel, lotion                                    | Apply topically to the affected area(s) BID  | varies |
| diflorasone 0.05% (Florone <sup>®</sup> , Florone E <sup>®</sup> , Maxiflor <sup>®</sup> , Psorcon E <sup>®</sup> ) cream |  |        |
| fluocinonide acetone 0.05% (Lidex <sup>®</sup> , Lidex E <sup>®</sup> ) cream, ointment, gel, solution                    |  |        |
| triamcinolone acetonide 0.5% (Aristocort <sup>®</sup> , Kenalog <sup>®</sup> ) cream, ointment                            |  |        |
| <b>Medium Potency Topical Corticosteroids</b>   |  |        |
| desoximetasone 0.05% (Topicort <sup>®</sup> ) cream, ointment, gel  | Apply topically to the affected area(s) BID  | varies |
| fluocinolone acetonide 0.025% (Synalar <sup>®</sup> ) cream, ointment   |  |        |
| mometasone 0.1% (Elocon <sup>®</sup> ) cream, ointment, lotion  |  |        |
| triamcinolone acetonide 0.025%, 0.1% (Aristocort <sup>®</sup> , Kenalog <sup>®</sup> ) cream, ointment                    |  |        |
| <b>Low Potency Topical Corticosteroids</b>  |  |        |
| alclometasone 0.05% (Aclovate <sup>®</sup> ) cream, ointment  | Apply topically to the affected area(s) BID  | varies |
| desonide 0.05% (Desowen <sup>®</sup> ) cream, ointment, lotion  |  |        |
| fluocinolone acetonide 0.01% (Synalar <sup>®</sup> ) solution   |  |        |
| hydrocortisone 2.5% (Hytone <sup>®</sup> ) cream, ointment  |  |        |
| <b>Other Classes of Agents</b>  |  |        |
| Protopic <sup>®</sup> (tacrolimus), Elidel <sup>®</sup> (pimecrolimus)  | Children $\geq$ 2 years and adults: Apply a thin layer topically to affected skin BID. Treatment should be discontinued if resolution of disease occurs. | varies |
| Eucrisa <sup>™</sup> (crisaborole)  | Apply to the affected areas BID  | varies |

|   |                                    |              |
|---|------------------------------------|--------------|
| cyclosporine  | 3-6mg/kg/day PO BID                | 300 mg/day   |
| azathioprine  | 1-3mg/kg/day PO once daily         | Weight-based |
| methotrexate  | 7.5-25mg/wk PO once weekly         | 25 mg/week   |
| mycophenolate mofetil   | 1-1.5 PO BID                       | 3 g/day      |
| Systemic corticosteroids (e.g. prednisone, prednisolone, triamcinolone) | PO, IM, or parenteral; dose varies | varies       |

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

**Appendix C: General Information**

- The Phase III pivotal studies (SOLO 1 and SOLO 2) of Dupixent showed no significant difference in clinical outcomes between dosing of Dupixent every week and every other week.

**V. Dosage and Administration**

| Indication                           | Dosing Regimen  | Maximum Dose            |
|--------------------------------------|---|-------------------------|
| Moderate-to-severe atopic dermatitis | Initial dose of 600 mg via subcutaneous injection, followed by 300 mg subcutaneously given every other week | 300 mg every other week |

**VI. Product Availability**

Injection: 300 mg/2 mL solution in a single-dose pre-filled syringe with or without needle shield

**VII. References**

- Dupixent Prescribing Information. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; March 2017. Available at [www.dupixent.com](http://www.dupixent.com). Accessed November 15, 2017.
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *New England Journal of Medicine*. 2016; 375: 2335-48.
- Eichenfield F, Tom WL, Chamlin SL et al. Guidelines of Care for the Management of Atopic Dermatitis. *J Am Acad Dermatol*. 2014 February; 70(2): 338–351.
- Leshem YA, Hajar T, Hanifin JM, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. *British Journal of Dermatology* 2015; 172(5):1353-1357.

| Reviews, Revisions, and Approvals  | Date     | P&T Approval Date |
|--|----------|-------------------|
| New policy   | 04.17    | 05.17             |
| 1Q18 annual review:<br>- Policies combined for HIM, Medicaid and commercial<br>- No significant changes<br>- References were reviewed and updated. | 11.15.17 | 02.18             |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**For Health Insurance Marketplace members**, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.